secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001493152-25-009335
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia
--------------------------------------------------------------------------------

- Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.
- Trial is randomized, double-blind, placebo-controlled; nine doses over five days, first dose within 12 hours of injury.
- Prior Phase I confirmed safety and tolerability at multiple intranasal doses in healthy adults.
- No FDA-approved drug therapies currently exist for concussion, an unmet medical need.
- Interim CEO Janet Huffman anticipates final regulatory approvals in coming weeks to initiate trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225009335/0001493152-25-009335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225009335/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer